• Gemcitabine-eribulin offers an alternative in metastatic urothelial cancer

    Positive phase 2 data in cisplatin-ineligible patients.

  • Surgery vs radiotherapy for high-grade prostate cancer with low PSA

    Data favor RP, but radiotherapy plus brachytherapy is a good option for elders.

  • Bladder cancer: survival outcomes similar with robotic vs open cystectomy

    Findings from a large multinational trial of 9.7K patients.

  • Smoking tied to risk for renal cancer in meta-analysis

    Risk rises with smoking intensity and duration.

  • Urothelial cancer: enfortumab vedotin active after platinum, anti-PD-1/L1 therapy

    Favorable phase 2 findings validate Nectin-4 as a therapeutic target.

  • Prostate cancer: extreme RT hypofractionation reduces toxicity, maintains outcomes

    Oncologic outcomes were similar to that of moderate hypofractionation.

  • Prostate cancer: adjuvant radiotherapy cuts risk for biochemical recurrence

    Study shows benefit in patients with positive margins or extracapsular extension.

  • FDA approves darolutamide for nonmetastatic CRPC

    Phase 3 ARAMIS showed significant improvement in metastasis-free survival.

  • Optimal first-line therapy in cisplatin-ineligible metastatic urothelial cancer

    Large cohort study compares immunotherapy and carboplatin-based chemotherapy.

  • CKD ups complication risk after radical prostatectomy

    Robotic-assisted surgery may attenuate risk in patients with CKD.

  • Erdafitinib nets 40% response rate in advanced urothelial cancer

    Findings led to accelerated FDA approval.

  • Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer

    NICE recommends special arrangements for clinical use

  • Metastatic, hormone-sensitive prostate cancer: add-on enzalutamide delays progression

    Phase 3 ARCHES trial reports 61% reduction in risk for progression or death.

  • Oligorecurrent prostate cancer: nodal radiotherapy shows reduced recurrences but higher toxicity

    Large multicenter retrospective analysis compares ENRT and SBRT.

  • Prostate cancer: recommendations on Gleason score and ISUP staging
    Prostate cancer: recommendations on Gleason score and ISUP staging

    The proposed recommendations are based on a review of existing guidance and published literature.

  • Bladder cancer: frailty predicts higher in-hospital mortality after surgery

    ICU-level complications, nonhome discharge.

  • Cochrane: is robotic cystectomy preferable for bladder cancer?

    A meta-analysis of 5 randomized trials.

  • Load more